Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Mar 1, 2026
Reporting period
Not applicable
Filed with the SEC
Mar 3, 2026
CFOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001682852-26-000038
Filed / recorded
Mar 3, 2026, 9:04 PM UTC
Added to OQRO
Oct 2, 2026, 12:28 PM UTC
Parser
form4-xml-v1
Data quality
Verified: identifiers matched exactly
Issuer
Moderna, Inc.
Issuer CIK
1682852
Ticker
MRNA
Reporting person
James M Mock
Relationship
Officer
Officer title
Chief Financial Officer
Security
Stock Option (Right to Buy)
Table
Derivative (Table II)
Transaction date
Mar 1, 2026
Transaction code
A
Shares / units
37,639
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
37,639
Ownership form
Direct
Amendment
No
Footnotes from the filing
25% of this option will vest and become exercisable on March 1, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter.